Catalytic Wealth RIA LLC Buys New Holdings in Illumina, Inc. (NASDAQ:ILMN)

Catalytic Wealth RIA LLC purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,629 shares of the life sciences company’s stock, valued at approximately $212,000.

A number of other large investors also recently modified their holdings of ILMN. UMB Bank n.a. boosted its stake in Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after acquiring an additional 88 shares in the last quarter. Integrated Advisors Network LLC boosted its position in shares of Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after purchasing an additional 90 shares during the period. Carson Advisory Inc. grew its stake in Illumina by 3.8% during the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after buying an additional 102 shares during the last quarter. Institute for Wealth Management LLC. increased its position in Illumina by 4.6% during the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock worth $285,000 after buying an additional 119 shares during the period. Finally, Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 0.3 %

Shares of ILMN stock opened at $151.50 on Tuesday. Illumina, Inc. has a fifty-two week low of $92.26 and a fifty-two week high of $156.66. The company has a quick ratio of 0.86, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business has a fifty day simple moving average of $138.09 and a 200-day simple moving average of $123.55. The stock has a market cap of $24.03 billion, a P/E ratio of -15.21 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 earnings per share. On average, analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ILMN. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Royal Bank of Canada upped their target price on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. TD Cowen raised their price target on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $120.00 to $154.00 in a research note on Friday, August 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $163.71.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.